» Articles » PMID: 28235788

A Systems Genetics Approach Identifies As a Link Between Cardiomyocyte Glucose Utilization and Hypertrophic Response

Abstract

Cardiac failure has been widely associated with an increase in glucose utilization. The aim of our study was to identify factors that mechanistically bridge this link between hyperglycemia and heart failure. Here, we screened the Hybrid Mouse Diversity Panel (HMDP) for substrate-specific cardiomyocyte candidates based on heart transcriptional profile and circulating nutrients. Next, we utilized an in vitro model of rat cardiomyocytes to demonstrate that the gene expression changes were in direct response to substrate abundance. After overlaying candidates of interest with a separate HMDP study evaluating isoproterenol-induced heart failure, we chose to focus on the gene as a cardiomyocyte glucose utilization-specific factor. gene knockdown in rat cardiomyocytes reduced expression and protein abundance of key glycolytic enzymes. This resulted in reduction of both glucose uptake and glycogen content in cardiomyocytes stimulated with isoproterenol. Furthermore, this reduction effectively blunted the capacity of glucose and isoprotereonol to synergistically induce hypertrophic gene expression and cell size expansion. We conclude that serves as regulator of cardiomyocyte glycolytic activity and can consequently regulate hypertrophic response in the context of elevated glucose content. Here, we apply a novel method for screening transcripts based on a substrate-specific expression pattern to identify as an induced cardiomyocyte glucose utilization factor. We further show that reducing expression of the gene could effectively blunt hypertrophic response in the context of elevated glucose content.

Citing Articles

DOR activation in mature oligodendrocytes regulates α-ketoglutarate metabolism leading to enhanced remyelination in aged mice.

Huang G, Li Z, Liu X, Guan M, Zhou S, Zhong X Nat Neurosci. 2024; 27(11):2073-2085.

PMID: 39266660 DOI: 10.1038/s41593-024-01754-9.


Metabolic status differentiates Trp53inp2 function in pressure-overload induced heart failure.

Liu J, Liu T, Ren S, Zhu C, Bouso E, Mamlouk S Front Cardiovasc Med. 2024; 10:1226586.

PMID: 38188257 PMC: 10766701. DOI: 10.3389/fcvm.2023.1226586.


Genetic architecture of heart mitochondrial proteome influencing cardiac hypertrophy.

Chella Krishnan K, El Hachem E, Keller M, Patel S, Carroll L, Vegas A Elife. 2023; 12.

PMID: 37276142 PMC: 10241513. DOI: 10.7554/eLife.82619.


The potential of integrating human and mouse discovery platforms to advance our understanding of cardiometabolic diseases.

Jurrjens A, Seldin M, Giles C, Meikle P, Drew B, Calkin A Elife. 2023; 12.

PMID: 37000167 PMC: 10065800. DOI: 10.7554/eLife.86139.


Multi-Omic Approaches to Identify Genetic Factors in Metabolic Syndrome.

Clark K, Kwitek A Compr Physiol. 2021; 12(1):3045-3084.

PMID: 34964118 PMC: 9373910. DOI: 10.1002/cphy.c210010.


References
1.
Hamilton C, Saggerson E . Malonyl-CoA metabolism in cardiac myocytes. Biochem J. 2000; 350 Pt 1:61-7. PMC: 1221224. View

2.
Doenst T, Nguyen T, Abel E . Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res. 2013; 113(6):709-24. PMC: 3896379. DOI: 10.1161/CIRCRESAHA.113.300376. View

3.
Pi Y, Walker J . Diacylglycerol and fatty acids synergistically increase cardiomyocyte contraction via activation of PKC. Am J Physiol Heart Circ Physiol. 2000; 279(1):H26-34. DOI: 10.1152/ajpheart.2000.279.1.H26. View

4.
Ventura-Clapier R, Garnier A, Veksler V . Energy metabolism in heart failure. J Physiol. 2003; 555(Pt 1):1-13. PMC: 1664831. DOI: 10.1113/jphysiol.2003.055095. View

5.
Iribarren C, Karter A, Go A, Ferrara A, Liu J, Sidney S . Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001; 103(22):2668-73. DOI: 10.1161/01.cir.103.22.2668. View